Chalk up another big win for Hal Barron and his R&D team extraordinaire at Genentech. The FDA today approved a new indication for Roche's ($RHHBY) cancer drug Avastin.
Targeted drugs are becoming the focus of a growing number of companies, and manufacturers are responding by building more antibody drug conjugate manufacturing capacity.
The Department of Homeland Security said it stepped up efforts to stop counterfeit products last year but ended up intercepting significantly fewer counterfeit pharmaceuticals than the year before.
Synthon Biopharmaceuticals' lead second-generation antibody-drug conjugate (ADC) has shown promise in breast and lung cancers grafted into animals, and a clinical trial is planned for 2014.
Investors rallied around Life Technologies amid buzz that the major provider of DNA sequencers could be on the block, with big names in private equity in the discussion as those approached to make an offer.
Roche's ($RHHBY) Genentech unit launched a new late-stage trial testing a two-drug combo in melanoma patients.
In yet another effort to get a handle on illegal drug manufacturing, the Chinese government says it will now pay 300,000 yuan ($48,250) for information that helps it catch offenders, up from the 50,000 yuan ($8,000) it had been paying.
Illumina ($ILMN) may have rebuffed M&A overtures from Roche ($RHHBY) at least three times now by our count. But CEO Jay Flatley insists he's not necessarily married to the idea of keeping the gene sequencing and diagnostics company independent.
Any discussion on the near-term future of Big Pharma starts with a review of the top drugs in Phase III. And this year's crop includes a collection of some high-flying blockbuster prospects that has analysts encouraged enough to allow that the productivity gains seen over the last two years could translate into some big new approvals in 2013.
Academic investigator John C. Reed, the top executive at the prestigious Sanford-Burnham Medical Research Institute in La Jolla has been named as the new chief at Roche's Pharma Research & Early Development, better known as pRED.